Bleomycin induces endothelial mesenchymal transition through activation of mTORpathway: a possible mechanism contributing to the sclerotherapy of venous malformations
Authors:
Open Access
- 28 August 2013
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 170 (6) , 1210-1220
Abstract
Background and Purpose: Bleomycin (BLM), one of the most common sclerosants, is often used to treat venous malformations (VMs). The present study was designed to investigate whether endothelial mesenchymal transition (EndoMT) contributes to the therapeutic effects ofBLM.Experimental Approach: Endothelial and mesenchymal markers of HUVECs were measured by immunofluorescence, real‐time quantitative PCR and Western blot analysis. Cell migration and tube formation assays were performed to evaluate endothelial cell function. Slug small‐interferingRNAand specific inhibitors [Z‐VAD‐FMK for pan caspases, rapamycin for mammalian target of rapamycin (mTOR)] were used to investigate the mechanism.Key Results: Long term (48 h or longer) treatment withBLM(0.1 mU·mL−1) inducedEndoMTinHUVECs, as manifested by a reduction in the expression of vascular endothelial‐cadherin and an up‐regulation in the expression of α‐smooth muscle actin and fibroblast specific protein‐1, as well as activation of the transcription factor Slug. The size and protein content of the transformed cells were increased. BLM also enhanced the migration of HUVECs but diminished their tube formation. By employing rapamycin, we demonstrated that activation of the mTORpathway is involved inBLM‐inducedEndoMTinHUVECs.Conclusions and Implications: Our results show that a Slug‐dependentEndoMTprocess is involved inBLM‐induced therapeutic effects on endothelial cells and, more importantly, indicate the potential role of this process in the sclerotherapy ofVMs.Keywords
This publication has 40 references indexed in Scilit:
- Sclerotherapy for vascular malformations: Complications and a review of techniques to avoid themJournal of Plastic, Reconstructive & Aesthetic Surgery, 2013
- The PI3K/Akt/mTOR signaling pathway mediates insulin-like growth factor 1-induced E-cadherin down-regulation and cell proliferation in ovarian cancer cellsCancer Letters, 2012
- Transforming growth factor-β2 promotes Snail-mediated endothelial–mesenchymal transition through convergence of Smad-dependent and Smad-independent signallingBiochemical Journal, 2011
- Treatment with rapamycin prevents fibrosis in tight‐skin and bleomycin‐induced mouse models of systemic sclerosisArthritis & Rheumatism, 2010
- Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effectsEuropean Journal of Human Genetics, 2009
- Epithelial-Mesenchymal Transitions in Development and DiseaseCell, 2009
- Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancersDrug Resistance Updates, 2008
- Endothelial-to-mesenchymal transition contributes to cardiac fibrosisNature Medicine, 2007
- Cell size and invasion in TGF-β–induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathwayJournal of Cell Biology, 2007
- Endothelial-Mesenchymal Transition Occurs during Embryonic Pulmonary Artery DevelopmentEndothelium, 2005